金河生物科技股份有限公司 2025年度业绩预告

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of over 50% compared to the previous year, despite positive sales growth in its veterinary pharmaceutical segment and increased revenue from its environmental services division [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a positive net profit but with a decline exceeding 50% [1]. Group 2: Sales and Revenue Drivers - The veterinary pharmaceutical segment continues to perform well, with increased sales in both domestic and international markets, particularly for the product "金霉素" [2]. - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating additional profits [2]. - The environmental services segment has also seen a rise in revenue, contributing significantly to overall performance [2]. Group 3: Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 174.99 million yuan related to the acquisition of 金河佑本 (Jilin) Biotechnology Co., Ltd., which will reduce the net profit attributable to shareholders by about 149.81 million yuan for the year 2025 [2].